A. Zweibach

发表

Loosening of cell cycle controls of human lymphocytes under the action of tumour promoter TPA

S. Ezhevsky, A. Vinogradov, J. M. Rosanov, 1991, Cell proliferation.

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.

J. Burke, K. Kolibaba, I. Flinn, 2021, The Lancet. Haematology.

UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY

S. Kambhampati, J. Burke, I. Flinn, 2017 .

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.

J. Burke, K. Kolibaba, I. Flinn, 2017 .